WOODBRIDGE, ON, May 6, 2014 /CNW/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, is pleased to announce that it presented two posters at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2014 Scientific Sessions held in Toronto, Ontario, Canada, May 1-3, 2014. Both posters discussed Omega-3 deficiency (OM3D) and VASCAZEN®'s unique formulation to correct the deficiency.
The first poster entitled "Correlation Between the Whole Blood Omega-Score®, and Red Blood Cell Membrane Omega-3 Index in a Patient Population with Cardiovascular Disease Risk Factors, Treated with VASCAZEN® a Unique Omega-3 Formulation" was presented on Friday, May 2, 2014. Omega-3 deficiency is commonly evaluated by using two commercially available blood tests, the Omega-Score® and Omega-3 Index that measure whole blood or red blood cell membrane Omega-3 levels respectively. As evidenced by this study, the Omega-Score® and Omega-3 Index give highly similar comparative results and can be used interchangeably to evaluate OM3D.
"The high degree of correlation between the Omega-Score® and Omega-3 Index allows healthcare practitioners to use either reimbursable test when testing for OM3D. The identification and the correction of an OM3D is an important part of managing a cardiac patients disease and may assist with patient compliance," stated Dr. George Jackowski, Chief Scientific Officer. "We are very excited with these results as we are in the process of developing a rapid format point of care test (POCT) for measuring blood levels of Omega-3's for the physicians office," added Dr. George Jackowski, Chief Scientific Officer.
The second poster entitled "Correction of Long Chain Omega-3 Fatty Acids Deficiency with a unique Omega-3 Formulation is Associated with a Significant Reduction in Atherogenic Index of Plasma in Hypertriglyceridemic Patients: Results from the VASCAZEN®-REVEAL Trial" was presented on Saturday, May 3rd, 2014. Atherogenicity index of plasma (AIP) is an emerging risk predictor for cardiovascular disease. The poster demonstrated that a correction of an Omega-3 deficiency in patients with hypertriglyceridemia (200-500 mg/dl) resulted in a significant decrease in AIP (-45%) within eight weeks of treatment with VASCAZEN®.
"The second presentation is a follow-up analysis of the VASCAZEN®-REVEAL Trial and illustrates that correcting an OM3D with VASCAZEN® has multiple benefits in cardiovascular patients, from helping support circulation, to promoting proper inflammatory responses in the body, and helping support normal triglyceride levels" said Dr. Jackowski, Chief Scientific Officer.
VASCAZEN® is currently available in the U.S. as a prescription only Medical Food specifically formulated for the dietary management of an Omega-3 deficiency in cardiovascular patients. VASCAZEN® is a >90% pure Omega-3 with a proprietary 6:1 EPA:DHA fatty acid formulation, protected by a series of both U.S. and foreign patents.
VASCAZEN® has been clinically shown to correct an Omega-3 deficiency within eight weeks of treatment with positive concomitant effects on the lipid profiles, mainly a 48% reduction of triglycerides and an increase of HDL without negative impact on the LDL-C lipid profile. VASCAZEN®'s results were achieved with a dose of 3 grams of EPA and DHA per day of a prescription grade, high purity Omega-3.
About Pivotal Therapeutics Inc.
Pivotal Therapeutics is a publicly traded (OTCQX: PVTTF) (CSE: PVO) specialty pharmaceutical company with a focus on cardiovascular disease and overall health. Pivotal Therapeutics' lead product VASCAZEN® is a prescription only Medical Food formulated to meet the dietary Omega-3 deficient needs of patients with cardiovascular disease through elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to levels associated with reduced risk of cardiovascular complications. OMAZEN® is a pharmaceutical grade Omega-3 providing over 90% pure Omega-3 in each capsule for the maintenance of good health. OMAZEN® is a patented product available for sale and distribution in Canada.
The information contained in this document is as of May 6, 2014. This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause Pivotal's actual results to differ materially from those projected in such forward-looking statements. These statements can be identified by the use of words such as "will", "anticipate", "estimate", "expect", "project", "forecast", "intend", "plan", "believe", "project", "potential", and similar expressions with any discussion of future operating or financial performance or events. In particular, factors that could cause actual results to differ materially from those in forward looking statements include the following: Pivotal's inability to obtain additional financing on acceptable terms; growth in costs and expenses; inability to compete with others who provide comparable products; risk that the Company's products will not gain widespread market acceptance; risks relating to the Company's ability to maintain its CSE listing. Forward-looking statements speak only as of the date made and are not guarantees of future performance. The Company undertakes no obligation to publicly update or revise any forward-looking statements contained in this document as a result of new information or future events or developments. CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this information.
SOURCE: Pivotal Therapeutics Inc.
For further information: Rachelle MacSweeney, President and Chief Operating Officer, Phone: 905-856-9797, E-Mail: [email protected]; Kristine DiMatteo, Communications and Public Relations Manager, Phone: 905-856-9797 ext. 231, E-Mail: [email protected]; www.pivotaltherapeutics.us